http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101976782-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate | 2017-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101976782-B1 |
| titleOfInvention | Composition for preventing or treating cancer comprising soluble common gamma chain inhibitor |
| abstract | The present invention relates to a pharmaceutical composition for preventing or treating cancer, which comprises a soluble common gamma chain inhibitor, and an anticancer therapeutic agent containing the inhibitor. In addition, the present invention relates to an aptamer specifically targeting a water soluble common gamma receptor. The pharmaceutical composition for preventing or treating cancer, which comprises the water soluble common gamma receptor inhibitor according to the present invention, targets sγc and inhibits its activity, thereby enhancing the anticancer response of cytotoxic CD8 + T cells. Sγc suppresses the cytotoxic response of CD8 + T cells by inhibiting the signal transduction pathways of IL-2 and IL-15 among γc cytokines, which are important for the survival and proliferation of CD8 + T cells. And can be used as a new chemotherapeutic method for promoting the function of cells. |
| priorityDate | 2017-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 200.